Treatment of breast carcinoma recurrent after adjuvant chemoimmunotherapy

✍ Scribed by Sami J. Rabadi; Max Haid; Edward F. Scanlon; Janardan D. Khandekar; Joseph A. Caprini; Miguel A. Oviedo; Myles P. Cunningham; Kerry K. Grizenko; Eli Cohen

• Publisher: John Wiley and Sons
• Year: 1984
• Tongue: English
• Weight: 442 KB
• Volume: 26
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930260407

✦ Synopsis

194 patients with State I1 or I11 breast carcinoma were randomized to receive either L-phenylalanine mustard (L-PAM), cyclophosphamide and 5-fluorouracil and prednisolone (CFP) , or CFP and BCG. Sixty-one patients have recurred despite the adjuvant chemoimmunotherapy trial. Fifty-three are evaluable for survival and 36 for response to chemo-hormonal therapy. Those treated with a chemohormonal regimen for their first recurrence exhibited a 53% objective response rate to cytotoxic therapy or a 35 % response to hormonal therapy. Prior exposure to L-PAM, cyclophosphamide, or 5-fluorouracil did not preclude response to "salvage" therapy regimens containing those agents. Neither menopausal status, estrogen receptor content, size of the primary tumor, adjuvant treatment, nor extent of the recurrence had any effect on subsequent survival. Overall, the entire group exhibitied median survival of 37 months from initial diagnosis and 13 months from recurrence. Unlike recurrent Hodgkin's disease, there was no demonstrable relationship between the length of the disease-free interval and the likelihood of subsequent response to cytotoxic or hormonal treatment. Comparison is made to the results of "salvage" therapy administered after three other large adjuvant treatment series.